Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, has been making strides in the biotechnology sector with its focus on developing anti-cancer drug candidates. Headquartered in Houston, Texas, the company operates within the Health Care sector and is listed on the Nasdaq stock exchange. As of December 4, 2025, Moleculin Biotech’s stock closed at $7.24, reflecting a significant fluctuation over the past year, with a 52-week high of $91.25 on February 12, 2025, and a 52-week low of $6.01 on November 30, 2025. The company’s market capitalization stands at $14,986,800 USD.
Founded with an Initial Public Offering (IPO) on June 2, 2016, Moleculin Biotech has been dedicated to advancing treatments for cancer and skin diseases. The company’s strategic focus on anti-cancer therapies positions it as a notable player in the biotechnology industry, which is increasingly prioritizing innovative cancer treatments. Despite the challenges inherent in drug development, Moleculin Biotech continues to pursue its mission of bringing effective therapies to market.
The company’s financial metrics, including a Price Earnings (P/E) ratio of -0.138, indicate the speculative nature of its stock, reflecting the high-risk, high-reward environment typical of biotechnology firms in the preclinical and clinical stages. Investors and stakeholders are closely monitoring Moleculin Biotech’s progress in its drug development pipeline, which is crucial for the company’s future growth and valuation.
Moleculin Biotech’s commitment to innovation is evident in its ongoing research and development efforts. The company’s portfolio includes several promising drug candidates aimed at addressing unmet medical needs in oncology and dermatology. By leveraging cutting-edge scientific research and clinical expertise, Moleculin Biotech aims to deliver transformative therapies that improve patient outcomes.
As the company navigates the complexities of drug development, it remains focused on its long-term vision of becoming a leader in the biotechnology sector. With a dedicated team of scientists and researchers, Moleculin Biotech is poised to make significant contributions to the field of medicine, particularly in the fight against cancer.
For more information about Moleculin Biotech, Inc., stakeholders and interested parties can visit the company’s website at www.moleculin.com . The company continues to engage with the scientific community, investors, and patients to advance its mission of developing innovative therapies that address critical health challenges.
